TVM Capital Life Science
Marc Rivière is currently the General Partner at TVM Capital, and also a Partner at MRCL Inc., focusing on drug development and health care management. Prior to these roles, Marc held various high-level positions in companies such as Aptalis Pharma, Caprion Pharma Inc., Bioniche Life Sciences, Xenon Pharmaceuticals Inc., Planet Medica SA, Aeterna Laboratories Inc, and Benefit Canada Inc./Quintiles Canada Inc. Marc's educational background includes a Doctor of Medicine degree from Université Paul Sabatier Toulouse III and Université de Bordeaux, with a specialization in Tropical Medicine.
This person is not in any offices
TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.